Nestlé's $2.6B Aimmune bet flopped: world's only peanut allergy drug up for sale

Palforzia is oral immunotherapy that gradually exposes allergic children to peanut doses to blunt severe reactions; hospitals and clinics administer it

Families and clinics will adopt the first FDA-approved peanut allergy treatment despite biweekly doctor visits and complex billing

Nestlé bought Palforzia's maker, Aimmune Therapeutics, for $2.6B in 2020

Nestlé, the packaged-food giant, bought Aimmune Therapeutics for $2.6B after the FDA approved Palforzia in January 2020 — the first and only approved drug to lessen allergic reactions to peanuts in children aged 4 to 17, working by gradually exposing children to higher doses of the nut to lower the risk of anaphylaxis.

Uptake lagged expectations. Providers were discouraged by complicated billing procedures; many families could not commit to the required doctor visits every two weeks for several months; and the pandemic arrived just after approval, keeping patients away from clinics. Parents testified to real gains — Katie Turner said the drug saved her son Ian after he drank a peanut butter smoothie unharmed — but by late 2022 Nestlé confirmed it was exploring 'strategic options' for the drug, which experts read as a likely sale, two years after the acquisition.

Complicated billing pushed providers out of offering the treatment at all

Biweekly clinic visits for months were more than many families could schedule

The pandemic began right after approval, freezing the clinic visits the protocol requires

A clinically real product still fails commercially when the treatment protocol — clinic visits, billing — is heavier than the benefit patients can schedule around

As of 2022-12-02 Nestlé would not speculate on next steps; a sale could widen availability, but with no buyer the treatment's future — and the signal for food-allergy drug investment — was uncertain.